AstraZeneca Plc declares results

  • Feb 14, 2020 GMT
  • Team Kalkine
  • Full year 2019 product sales growth came in at 12% to $23,565 million
  • Sales of new medicine came in at $9,906 million
  • Sales growth in Oncology was 44% while that for respiratory diseases was 10%
  • Sales growth in emerging markets was at 18%
  • On 14th February 2020, at the time of writing, GMT 09:52 AM, AZN shares were trading at GBX 7,594, down by 32 points or 0.42% against the previous day closing price


With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK